Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A (1)H-Magnetic Resonance Spectroscopy Study

BACKGROUND: Antiangiogenic treatment of glioblastomas with Bevacizumab lacks predictive markers. Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since Bevacizumab markedly reduces tumor edema and influences the tumor microe...

Descripción completa

Detalles Bibliográficos
Autores principales: Steidl, Eike, Pilatus, Ulrich, Hattingen, Elke, Steinbach, Joachim P., Zanella, Friedhelm, Ronellenfitsch, Michael W., Bähr, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198997/
https://www.ncbi.nlm.nih.gov/pubmed/28033329
http://dx.doi.org/10.1371/journal.pone.0168113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198997/
https://www.ncbi.nlm.nih.gov/pubmed/28033329
http://dx.doi.org/10.1371/journal.pone.0168113

Ejemplares similares